Defect-Engineered MOF Catalyst Enables Efficient Synthesis of Medicinally Important Compounds
Researchers have developed a novel defect-engineered MOF-303 catalyst that demonstrates exceptional performance in synthesizing dihydropyrimidinones, key pharmaceutical intermediates. The catalyst’s unique dual acid-base properties and enhanced porosity reportedly enable near-quantitative yields under sustainable conditions.
Breakthrough in Heterogeneous Catalysis
Scientific reports indicate that researchers have successfully engineered a defect-rich metal-organic framework (MOF-303) that serves as an efficient dual acid-base catalyst for synthesizing biologically important dihydropyrimidinones (DHPMs). According to the published study, this innovative catalyst demonstrates remarkable performance in the one-pot Biginelli reaction, achieving yields exceeding 99% under optimized conditions.